Salicylic acid: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(12 intermediate revisions by the same user not shown)
Line 2: Line 2:
|authorTag={{Ammu}}
|authorTag={{Ammu}}
|genericName=Salicylic acid
|genericName=Salicylic acid
|aOrAn=a
|aOrAn=an
|drugClass=anti acne agent
|drugClass=anti [[acne]] agent
|indicationType=treatment
|indicationType=treatment
|indication=[[acne]], for relief of [[itching]], irritation, redness and scaling assoicated with [[psoriasis]], [[eczema]] and [[seborrheic dermatitis]]
|indication=[[acne]], for relief of [[itching]], irritation, [[redness]] and scaling assoicated with [[psoriasis]], [[eczema]] and [[seborrheic dermatitis]]
|adverseReactions=[[hypersensitivity]] reaction, salicylate toxicity
|adverseReactions=[[hypersensitivity]] reaction, salicylate toxicity
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
Line 17: Line 17:
|fdaLIADAdult=* FOR THE TREATMENT OF ACNE
|fdaLIADAdult=* FOR THE TREATMENT OF ACNE
* HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES
* HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES
* For relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis.
* For relief of itching, irritation, redness and scaling assoicated with [[psoriasis]], [[eczema]] and [[seborrheic dermatitis]].
|offLabelAdultGuideSupport=* Acne vulgaris
|offLabelAdultGuideSupport=* [[Acne vulgaris]]
:* Apply TOPICALLY in concentrations of 0.5% to 10%
:* Apply TOPICALLY in concentrations of 0.5% to 10%
Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night.
:* Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night.
* Disorder of skin, Hyperkeratotic
* Disorder of skin, Hyperkeratotic
:* shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5]
:* shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5]
Line 27: Line 27:
* Removal of wart
* Removal of wart
:* Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks
:* Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=There is limited information regarding <i>FDA-labeled indications and dosage information</i> of {{PAGENAME}} in pediatric patients.
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
<!--Warnings-->
|warnings=* For external use only.
|warnings=* For external use only.
* Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
* Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Line 90: Line 45:
* Do not use for prolonged periods without consulting a doctor.
* Do not use for prolonged periods without consulting a doctor.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 111: Line 62:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|administration=* Topical
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 122: Line 70:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->


<!--Drug box 2-->
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|drugBox={{chembox2
|mechAction=*
| Watchedfields = changed
 
| verifiedrevid = 477314005
<!--Structure-->
| Name = Salicylic acid
|structure=*
| ImageFileL1 = Salicylic-acid-skeletal.svg
 
| ImageSizeL1 = 100px
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| ImageNameL1 = Skeletal formula of salicylic acid
 
| ImageFileR1 = Salicylic-acid-from-xtal-2006-3D-balls.png
<!--Pharmacodynamics-->
| ImageSizeR1 = 100px
| ImageNameR1 = Ball-and-stick model of salicylic acid
| ImageFile2 = Kwas salicylowy.jpg
| ImageSize2 = 200px
| ImageName2 = Salicylic acid
| IUPACName = 2-Hydroxybenzoic acid
| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O414PZ4LPZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00097
| InChI = 1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
| InChIKey = YGSDEFSMJLZEOE-UHFFFAOYAQ
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 424
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YGSDEFSMJLZEOE-UHFFFAOYSA-N
| CASNo = 69-72-7
| CASNo_Ref = {{cascite|correct|CAS}}
| PubChem = 338
| EINECS = 200-712-3
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 331
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00936
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 16914
| SMILES = c1ccc(c(c1)C(=O)O)O
| ATCCode_prefix = A01
| ATCCode_suffix = AD05
| ATC_Supplemental = {{ATC|B01|AC06}} {{ATC|D01|AE12}} {{ATC|N02|BA01}} {{ATC|S01|BC08}}
| RTECS = VO0525000
}}
| Section2 = {{Chembox Properties
| C=7|H=6|O=3
| Appearance = colorless to white crystals
| Odor = odorless
| MeltingPtC = 158.6
| BoilingPtC = 200
| Boiling_notes = <br> decomposes<ref name=chemister /><br> {{convert|211|C|F K}}<br> at 20 mmHg<ref name=crc>{{RubberBible92nd|page=3.306}}</ref>
| pKa = 1 = 2.97 (25 °C)<ref>[http://www.drugbank.ca/drugs/DB00936 Salicyclic acid]. Drugbank.ca. Retrieved on 2012-06-03.</ref><br> 2 = 13.82 (20 °C)<ref name=chemister />
| Density = 1.443 g/cm<sup>3</sup> (20 °C)<ref name=crc/>
| Solubility = 1.24 g/L (0 °C)<br> 2.48 g/L (25 °C)<br> 4.14 g/L (40 °C)<br> 17.41 g/L (75 °C)<ref name=chemister>http://chemister.ru/Database/properties-en.php?dbid=1&id=1777</ref><br> 77.79 g/L (100 °C)<ref name=sioc>{{cite book|last = Seidell|first = Atherton|last2 = Linke|first2 = William F.|year = 1952|title = Solubilities of Inorganic and Organic Compounds|publisher = Van Nostrand|url = [http://books.google.com/books?id=k2e5AAAAIAAJ Google Books]|accessdate = 2014-05-29}}</ref>
| SolubleOther = soluble in [[ether]], [[carbon tetrachloride|CCl<sub>4</sub>]], [[benzene]], [[propanol]], [[acetone]], [[ethanol]], [[oil of turpentine]], [[toluene]]
| Solubility1 = 0.46 g/100 g (11.7 °C)<br> 0.775 g/100 g (25 °C)<br> 0.991 g/100 g (30.5 °C)<br> 2.38 g/100 g (49.4 °C)<br> 4.4 g/100 g (64.2 °C)<ref name=chemister /><ref name=sioc />
| Solvent1 = benzene
| Solubility2 = 2.22 g/100 mL (25 °C)<ref name=sioc /><br> 2.31 g/100 mL (30.5 °C)<ref name=chemister />
| Solvent2 = chloroform
| Solubility3 = 40.67 g/100 g (−3 °C)<br> 62.48 g/100 g (21 °C)<ref name=chemister />
| Solvent3 = methanol
| Solubility4 = 2.43 g/100 g (23 °C)<ref name=chemister />
| Solvent4 = olive oil
| Solubility5 = 39.6 g/100 g (23 °C)<ref name=chemister />
| Solvent5 = acetone
| RefractIndex = 1.565 (20 °C)<ref name=crc/>
| LogP = 2.26
| VaporPressure = 10.93 mPa<ref name=pubchem>{{PubChemLink|338}}</ref>
| SublimationConditions = sublimes at 76 °C<ref name=pubchem />
| LambdaMax = 210 nm, 234 nm, 303 nm (4&nbsp;mg % in ethanol)<ref name=pubchem />
}}
| Section5 = {{Chembox Thermochemistry
| DeltaHf = -589.9 kJ/mol
| DeltaHc = 3.025 MJ/mol<ref name=NIST>http://webbook.nist.gov/cgi/cbook.cgi?ID=C69727&Type=HCOMBS</ref>
}}
| Section8 = {{Chembox Related
| OtherCpds = [[Methyl salicylate]],<br />[[Benzoic acid]],<br />[[Phenol]], [[Aspirin]],<br />[[4-Hydroxybenzoic acid]],<br /> [[Magnesium salicylate]],<br />[[Choline salicylate]],<br />[[Bismuth subsalicylate]],<br />[[Sulfosalicylic acid]]
}}
| Section6 = {{Chembox Hazards
| ExternalMSDS = [http://avogadro.chem.iastate.edu/MSDS/salicylic_acid.htm MSDS]
| GHSPictograms = {{GHS05}}{{GHS07}}<ref name="sigma">{{Sigma-Aldrich|id=w398500|name=Salicylic acid|accessdate=2014-05-23}}</ref>
| GHSSignalWord = Danger
| HPhrases = {{H-phrases|302|318}}<ref name="sigma" />
| PPhrases = {{P-phrases|280|305+351+338}}<ref name="sigma" />
| RPhrases = {{R22}}, {{R38}}, {{R41}}, {{R61}}
| SPhrases = {{S22}}, {{S26}}, {{S36}}, {{S37}}, {{S39}}
| EUClass = {{Hazchem Xn}}
| EUIndex = 200-712-3
| MainHazards =
| SkinHazard = Mild irritation
| EyeHazard = Severe irritation
| NFPA-H = 2
| NFPA-F = 1
| NFPA-R = 0
| NFPA-S =
| FlashPtC = 157
| Flash_notes = <br> closed cup<ref name=pubchem />
| AutoignitionPtC = 540
| Autoignition_ref = <ref name=pubchem />
| ExploLimits =
| PEL =
| LD50 = 480 mg/kg (mice, oral)
}}
}}
|mechAction=* Salicylic acid has been shown to work through several different pathways. It produces its anti-inflammatory effects via suppressing the activity of cyclooxygenase (COX), an enzyme that is responsible for the production of pro-inflammatory mediators such as the prostaglandins.
* It does this not by direct inhibition of COX like most other non-steroidal anti-inflammatory drugs (NSAIDs) but instead by suppression of the expression of the enzyme (via a yet-unelucidated mechanism).<ref name=American chemical society>{{cite web | title = American chemical society | url =http://www.cas.org/news/insights/science-connections/aspirin}}</ref>
* Salicylic acid has also been shown to activate adenosine monophosphate-activated protein kinase (AMPK), and it is thought that this action may play a role in the anticancer effects of the compound and its prodrugs aspirin and salsalate. In addition, the antidiabetic effects of salicylic acid are likely mediated by AMPK activation primarily through allosteric conformational change that increases levels of phosphorylation.<ref name="pmidPMID 22517326">{{cite journal| author=Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al.| title=The ancient drug salicylate directly activates AMP-activated protein kinase. | journal=Science | year= 2012 | volume= 336 | issue= 6083 | pages= 918-22 | pmid=PMID 22517326 | doi=10.1126/science.1215327 | pmc=PMC3399766 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22517326  }} </ref>
* Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ADP:ATP and AMP:ATP ratios in the cell. As a consequence, salicylic acid may alter AMPK activity and subsequently exert its anti-diabetic properties through altered energy status of the cell. Even in AMPK knock-out mice, however, there is an anti-diabetic effect, demonstrating that there is at least one additional, yet-unidentified action of the compound.
<ref name=Newscientist>{{cite web | title = Newscientist | url =http://www.newscientist.com/article/dn21718-clues-to-aspirins-anticancer-effects-revealed.html }}</ref>
|structure=<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


Line 160: Line 196:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=<!--Patient Counseling Information-->
 
<!--Patient Counseling Information-->
|fdaPatientInfo=* Wash affected areas well with soap and water. Pat dry. Apply cream to affected area one to four times per day, or as directed by physician.
|fdaPatientInfo=* Wash affected areas well with soap and water. Pat dry. Apply cream to affected area one to four times per day, or as directed by physician.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Line 168: Line 202:
<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ALA-SEPTIC®<ref>{{Cite web | title =ALA-SEPTIC- salicylic acid cream  | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb70750-bea8-4c0f-9453-f2c38d2f05d9  }}</ref>
|brandNames=* ALA-SEPTIC®<ref>{{Cite web | title =ALA-SEPTIC- salicylic acid cream  | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb70750-bea8-4c0f-9453-f2c38d2f05d9  }}</ref>
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
Line 178: Line 207:
|fileName=Saly 1.jpg
|fileName=Saly 1.jpg
}}
}}
{{LabelImage}}
{{LabelImage
|fileName=Saly 2.png
}}
{{LabelImage
|fileName=Saly 3.png
}}
{{LabelImage
|fileName=Saly 4.png
}}
<!--Pill Image-->
<!--Pill Image-->


Line 192: Line 229:


[[Category:Drug]]
[[Category:Drug]]
[[Category:Non-steroidal anti-inflammatory drugs]]
[[Category:Antiseptics]]

Latest revision as of 20:28, 4 March 2015

Salicylic acid
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Salicylic acid is an anti acne agent that is FDA approved for the treatment of acne, for relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis. Common adverse reactions include hypersensitivity reaction, salicylate toxicity.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • FOR THE TREATMENT OF ACNE
  • HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES
  • For relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

  • Apply TOPICALLY in concentrations of 0.5% to 10%
  • Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night.
  • Disorder of skin, Hyperkeratotic
  • shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5]
  • Psoriasis
  • Apply TOPICALLY in concentrations of 3% to 6%
  • Removal of wart
  • Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Salicylic acid in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-labeled indications and dosage information of Salicylic acid in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Salicylic acid in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Salicylic acid in pediatric patients.

Contraindications

There is limited information regarding Salicylic acid Contraindications in the drug label.

Warnings

  • For external use only.
  • Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
  • Do not use without consulting a doctor if the condition appears over a large portion of hte body.
  • If condition worsens, or does not improve after using as directed, consult physician.
  • Do not use for prolonged periods without consulting a doctor.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Salicylic acid in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Salicylic acid in the drug label.

Drug Interactions

There is limited information regarding Salicylic acid Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Salicylic acid in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Salicylic acid during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Salicylic acid with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Salicylic acid with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Salicylic acid with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Salicylic acid with respect to specific gender populations.

Race

There is no FDA guidance on the use of Salicylic acid with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Salicylic acid in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Salicylic acid in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Salicylic acid in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Salicylic acid in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Topical

Monitoring

There is limited information regarding Monitoring of Salicylic acid in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Salicylic acid in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Salicylic acid in the drug label.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox ECNumberTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox OdourTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SublimationConditionsTemplate:Chembox SolubilityInWaterTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox LogPTemplate:Chembox VaporPressureTemplate:Chembox pKaTemplate:Chembox LambdaMaxTemplate:Chembox RefractIndexTemplate:Chembox ThermochemistryTemplate:Chembox GHSPictogramsTemplate:Chembox GHSSignalWordTemplate:Chembox HPhrasesTemplate:Chembox PPhrasesTemplate:Chembox EyeHazardTemplate:Chembox SkinHazardTemplate:Chembox NFPATemplate:Chembox FlashPtTemplate:Chembox AutoignitionPtTemplate:Chembox Lethal amounts (set)Template:Chembox Supplement
Template:Chembox header2 | Salicylic acid
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
KEGG
UNII
Properties
C7H6O3
Molar mass 138.12 g·mol−1
Hazards
Related compounds
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

  • Salicylic acid has been shown to work through several different pathways. It produces its anti-inflammatory effects via suppressing the activity of cyclooxygenase (COX), an enzyme that is responsible for the production of pro-inflammatory mediators such as the prostaglandins.
  • It does this not by direct inhibition of COX like most other non-steroidal anti-inflammatory drugs (NSAIDs) but instead by suppression of the expression of the enzyme (via a yet-unelucidated mechanism).
  • Salicylic acid has also been shown to activate adenosine monophosphate-activated protein kinase (AMPK), and it is thought that this action may play a role in the anticancer effects of the compound and its prodrugs aspirin and salsalate. In addition, the antidiabetic effects of salicylic acid are likely mediated by AMPK activation primarily through allosteric conformational change that increases levels of phosphorylation.[7]
  • Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ADP:ATP and AMP:ATP ratios in the cell. As a consequence, salicylic acid may alter AMPK activity and subsequently exert its anti-diabetic properties through altered energy status of the cell. Even in AMPK knock-out mice, however, there is an anti-diabetic effect, demonstrating that there is at least one additional, yet-unidentified action of the compound.

[8]

Structure

There is limited information regarding Salicylic acid Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Salicylic acid in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Salicylic acid in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Salicylic acid in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Salicylic acid in the drug label.

How Supplied

There is limited information regarding Salicylic acid How Supplied in the drug label.

Storage

There is limited information regarding Salicylic acid Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Salicylic acid |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Salicylic acid |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

  • Wash affected areas well with soap and water. Pat dry. Apply cream to affected area one to four times per day, or as directed by physician.

Precautions with Alcohol

  • Alcohol-Salicylic acid interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • ALA-SEPTIC®[9]

Look-Alike Drug Names

There is limited information regarding Salicylic acid Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ 1.0 1.1 1.2 Template:RubberBible92nd
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Template:PubChemLink
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 http://chemister.ru/Database/properties-en.php?dbid=1&id=1777
  4. ↑ 4.0 4.1 4.2 Seidell, Atherton; Linke, William F. (1952). [Google Books Solubilities of Inorganic and Organic Compounds] Check |url= value (help). Van Nostrand. Retrieved 2014-05-29.
  5. ↑ Salicyclic acid. Drugbank.ca. Retrieved on 2012-06-03.
  6. ↑ 6.0 6.1 6.2 Template:Sigma-Aldrich
  7. ↑ Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ; et al. (2012). "The ancient drug salicylate directly activates AMP-activated protein kinase". Science. 336 (6083): 918–22. doi:10.1126/science.1215327. PMC 3399766. PMID 22517326 PMID 22517326 Check |pmid= value (help).
  8. ↑ "Newscientist".
  9. ↑ "ALA-SEPTIC- salicylic acid cream".

{{#subobject: 

 |Label Page=Salicylic acid
 |Label Name=Saly 1.jpg

}}

{{#subobject: 

 |Label Page=Salicylic acid
 |Label Name=Saly 2.png

}}

{{#subobject: 

 |Label Page=Salicylic acid
 |Label Name=Saly 3.png

}}

{{#subobject: 

 |Label Page=Salicylic acid
 |Label Name=Saly 4.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Salicylic_acid&oldid=1075090"